Dr Immunotherapy becomes CEO
01.04.2015 - This month, Kostas Kosmatopoulos segues from his current position as Vaxon Biotech’s founder and Chief Scientific Officer to his new role of Chief Executive Officer. As newly appointed CEO, he will use his extensive experience as a medical oncologist and immunologist to lead the company forward in its development in therapeutic vaccines.
In 2004, Kostas established Vaxon Biotech on the basis of his work as research director at Inserm, France’s national institute of health, and his work specialising in tumour immunotherapy at the Institute Gustave Roussy (IGR), a leading cancer research institute. The two institutes granted Vaxon Biotech an exclusive worldwide license for three patents. Vaxon subsequently filed seven more patents in its own name. The Paris-based biotech develops unique and innovative vaccine technology and uses ‘optimized cryptic peptides’ that significantly improve immune responses and therefore vaccine efficacy.
Kostas received his medical degree at the University of Thessaloniki, his medical oncology certification from Theagenion Cancer Research Institute, Greece, and his PhD in Immunology at Paris XI University, France. Kostas has co-authored more than 50 scientific and international publications.
“I am very enthusiastic and delighted to hold this new position at Vaxon Biotech, the company I founded ten years ago,” said Kostas. “I have always been convinced of its potential in anti-tumour immunotherapy, a very promising sector in oncology.”http://www.european-biotechnology-news.com/people/bio-people/2015/kostas-kosmatopoulos.html